PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)

Anemia poses risks during coronary artery bypass grafting (CABG), increasing complications and mortality rates. Blood transfusions in cardiac surgery have negative outcomes, prompting the use of erythropoietin in Patient Blood Management (PBM) to limit transfusion needs and enhance postoperative recovery. EPO can reduce blood component requirements, adverse events, and inflammation in anemic CABG patients. A study aims to minimize transfusions through a PBM anemia treatment protocol for CABG patients, comparing outcomes in three groups: a Control Group (CG), a Non-PBM Group (NPBMG) treated with blood components, and a PBM Group (GPBM) treated with EPO. Parameters include post-op stay, mortality, cardiovascular events, non-cardiovascular events, ICU time, mechanical ventilation duration, vasoactive drug use, inflammatory responses, and cardiac cell death. Analysis will consider demographic and clinical factors, with expectations that GPBM will yield superior results compared to NPBMG and similar or better outcomes than CG.

NCT Number	NCT06542393
Lead Sponsor	Federal University of São Paulo Collaborators: Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions	Anemia, Coronary Disease, Coronary Artery Disease, Coronary Stenosis, Coronary Occlusion, Systemic Inflammatory Response, Bleeding, Epigenetic Disorder
Enrollment	120 participants
Start Date	2024-06-01
Primary Completion	2025-06-01 (estimated)
Study Completion	2026-06-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-07